Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$133.08 USD

133.08
1,070,906

-0.38 (-0.28%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $133.07 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SRPT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Sarepta Therapeutics, Inc. [SRPT]

Reports for Purchase

Showing records 321 - 340 ( 672 total )

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 321

01/04/2019

Company Report

Pages: 12

Pipeline and Competitive Events Poised to Shape 2019 Outlook

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 322

01/03/2019

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 323

12/26/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 324

12/19/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 325

12/10/2018

Company Report

Pages: 11

First Mover Advantage Could Dissuade Competitive Launches; if Preliminary Peer Data Are Meaningfully Subpar

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 326

11/21/2018

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 327

11/16/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 328

10/25/2018

Company Report

Pages: 10

An In-line 3Q18; Our Go to Stock When Sanity Returns

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 329

10/22/2018

Company Report

Pages: 9

3Q18 Preview: Expecting Another Steady Eddy From Exondys 51; Focus Remains on Pipeline Execution

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 330

10/19/2018

Company Report

Pages: 11

Recent Pipeline Augmentation Likely Signals More to Follow; Updated on CMT and MPS IIIA

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 331

10/16/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 332

10/08/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 333

10/04/2018

Company Report

Pages: 9

Too Much of a Good Thing Is Not Necessarily a Bad Thing; Data Points to a Degree of Correlation With Micro-Dystrophin

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 334

09/24/2018

Daily Note

Pages: 9

Clinical Hold in the Rearview; Awaiting FDA Guidance on Registration Study Commencement by YE18

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 335

09/21/2018

Company Report

Pages: 9

CHMP Nod Would Have Been Icing on the Cake, But We''ll Take the Cake for Now

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 336

09/10/2018

Daily Note

Pages: 15

Pre-ASH Catalyst Calendar For Stocks Under Coverage

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 50.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 337

09/05/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 338

09/04/2018

Company Report

Pages: 12

A Summary of the Preclinical Pompe Disease, Gene Therapy Landscape

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 339

08/09/2018

Company Report

Pages: 9

Deploying $1B-From Zero to 11 Gene Therapy Programs in Less Than a Year; Core Morpholino Pipeline Humming Along

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 340

08/06/2018

Company Report

Pages: 8

Price: 24.95
// eof